Table 2.
Serum concentrations of estrogens and estrogen metabolites (pmol/L) among postmenopausal endometrial and ovarian cases and their respective subcohort members
| Estrogen measures (pmol/L) | Endometrial cases (n = 66) | Subcohorta (n = 346) | Ovarian cases (n = 67) | Subcohortb (n = 416) | ||||
|---|---|---|---|---|---|---|---|---|
| Median | 10th, 90th | Median | 10th, 90th | Median | 10th, 90th | Median | 10th, 90th | |
| Total estrogens and estrogen metabolites | 919.6 | 447.0, 2346.4 | 765.0 | 391.1, 1984.2 | 967.2 | 460.2, 2224.3 | 785.4 | 412.2, 1940.0 |
| Parent estrogens | 407.5 | 152.9, 1073.4 | 316.8 | 120.1, 852.8 | 412.2 | 153.3, 1037.2 | 332.8 | 133.6, 854.8 |
| Estrone | 344.1 | 131.8, 948.9 | 276.0 | 102.3, 768.8 | 361.0 | 136.4, 941.4 | 293.2 | 112.6, 768.8 |
| Estradiol | 53.8 | 30.0, 138.5 | 38.2 | 18.1, 91.4 | 45.8 | 16.6, 105.0 | 39.3 | 17.6, 91.5 |
| 2-Hydroxylation pathway | 131.0 | 188.3, 327.7 | 117.7 | 75.4, 257.6 | 133.4 | 81.1, 260.6 | 120.0 | 75.9, 250.5 |
| 2-Pathway catechols | 89.7 | 52.7, 205.6 | 75.2 | 46.5, 161.8 | 83.8 | 45.6, 174.0 | 77.3 | 46.8, 161.8 |
| 2-Hydroxyestrone | 75.6 | 45.1, 176.6 | 61.1 | 38.2, 140.8 | 71.1 | 36.5,149.3 | 63.7 | 38.7, 140.5 |
| 2-Hydroxyestradiol | 14.3 | 8.6, 29.0 | 12.5 | 7.5, 25.5 | 13.1 | 8.0, 28.6 | 12.3 | 7.5, 25.3 |
| 2-Pathway methylated catechols | 46.7 | 23.9, 114.3 | 45.0 | 24.2, 96.6 | 50.5 | 30.4, 110.1 | 46.8 | 24.7, 96.1 |
| 2-Methoxyestrone | 32.8 | 13.1, 94.7 | 27.6 | 13.8, 59.5 | 32.0 | 17.5, 85.9 | 28.2 | 13.9, 59.9 |
| 2-Methoxyestradiol | 10.4 | 7.0, 20.2 | 12.5 | 6.7, 24.0 | 14.3 | 6.8, 26.8 | 13.2 | 6.8, 24.2 |
| 2-Hydroxyestrone-3-methyl ether | 3.8 | 2.4, 10.0 | 4.0 | 2.2, 10.1 | 4.2 | 3.2, 13.5 | 4.0 | 2.29, 10.1 |
| 4-Hydroxylation pathway | 19.3 | 12.7, 40.0 | 16.8 | 11.2, 34.4 | 19.1 | 11.7, 34.8 | 17.0 | 11.3, 34.4 |
| 4-Hydroxyestrone (catechol) | 14.2 | 7.7, 29.1 | 10.7 | 6.4, 21.5 | 11.0 | 6.3, 22.1 | 10.7 | 6.5, 21.2 |
| 4-Pathway methylated catechols | 6.3 | 4.0, 10.6 | 6.6 | 3.7, 13.7 | 7.7 | 4.7, 15.5 | 6.7 | 3.8, 13.8 |
| 4-Methoxyestrone | 3.6 | 2.0, 8.2 | 3.7 | 2.1, 8.0 | 4.7 | 3.0, 11.2 | 3.8 | 2.2, 8.2 |
| 4-Methoxyestradiol | 2.6 | 1.2, 4.2 | 2.7 | 1.2, 5.7 | 3.3 | 1.7, 5.7 | 2.8 | 1.2, 5.8 |
| 16-Hydroxylation pathway | 359.7 | 188.3, 917.1 | 302.6 | 166.0, 749.6 | 377.2 | 183.4, 760.9 | 311.9 | 173.0, 749.6 |
| Estriol | 279.4 | 141.1, 687.2 | 239.2 | 123.8, 586.5 | 285.4 | 139.3, 544.9 | 245.9 | 130.7, 590.4 |
| 16α-Hydroxyestrone | 35.5 | 120.0, 84.9 | 28.1 | 17.8, 69.2 | 29.9 | 15.8, 75.1 | 28.5 | 17.6, 67.4 |
| 16-Epiestriol | 3.75 | 1.6, 18.2 | 3.8 | 1.6, 14.4 | 4.5 | 2.3, 19.0 | 4.0 | 1.7, 14.4 |
| 17-Epiestriol | 3.2 | 1.1, 8.0 | 3.4 | 1.3, 9.3 | 3.6 | 1.35, 10.5 | 3.5 | 1.4, 9.4 |
| 16-Ketoestradiol | 33.4 | 18.0, 82.5 | 29.0 | 17.7, 88.3 | 34.2 | 20.5, 100.5 | 30.3 | 18.0, 88.3 |
aIncludes subcohort members eligible for endometrial cancer analysis (no prior hysterectomy); subcohort includes four incident endometrial cancer cases
bIncludes subcohort members eligible for ovarian cancer analysis (no history of double oopherectomy)